Who are Contraceptive Vaginal Ring's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): oral contraceptives, ethinyl estradiol/etonogestrel vaginal ring, intramuscular depot medroxyprogesterone acetate, Etonogestrel/ethinyl estradiol vaginal ring, Ortho Tri Cyclen, oral contraceptive pills.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/contraceptive-vaginal-ring.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Contraceptive Vaginal Ring — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Contraceptive Vaginal Ring (Contraceptive Vaginal Ring) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hormonal contraceptive. Area: Contraception / Reproductive Health.

marketed Hormonal contraceptive Contraception / Reproductive Health Small molecule Live · refreshed every 30 min

Target snapshot

Contraceptive Vaginal Ring (Contraceptive Vaginal Ring) — Penn State University. Releases hormones (typically ethinyl estradiol and a progestin) directly into the vaginal tissue to prevent ovulation and thicken cervical mucus.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Contraceptive Vaginal Ring TARGET	Contraceptive Vaginal Ring	Penn State University	marketed	Hormonal contraceptive
oral contraceptives	oral contraceptives	FHI 360	marketed	Hormonal contraceptive	Estrogen receptor, Progesterone receptor
ethinyl estradiol/etonogestrel vaginal ring	ethinyl estradiol/etonogestrel vaginal ring	University of Pittsburgh	marketed	Combined hormonal contraceptive	Estrogen receptor and progesterone receptor
intramuscular depot medroxyprogesterone acetate	intramuscular depot medroxyprogesterone acetate	Prince of Songkla University	marketed	Progestin; hormonal contraceptive	Progesterone receptor
Etonogestrel/ethinyl estradiol vaginal ring	Etonogestrel/ethinyl estradiol vaginal ring	Andrea Roe, MD, MPH	marketed	Combined hormonal contraceptive	Progesterone receptor, estrogen receptor
Ortho Tri Cyclen	Ortho Tri Cyclen	Virginia Commonwealth University	marketed	Oral contraceptive (combined hormonal contraceptive)	Progesterone receptor, estrogen receptor
oral contraceptive pills	oral contraceptive pills	Kayseri Education and Research Hospital	marketed	Hormonal contraceptive	Estrogen receptor, Progesterone receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hormonal contraceptive class)

Penn State University · 2 drugs in this class
Italfarmaco · 1 drug in this class
Kayseri Education and Research Hospital · 1 drug in this class
TherapeuticsMD · 1 drug in this class
University of Alabama at Birmingham · 1 drug in this class
University of Athens · 1 drug in this class
FHI 360 · 1 drug in this class
University of Pittsburgh · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Contraceptive Vaginal Ring — Competitive Intelligence Brief. https://druglandscape.com/ci/contraceptive-vaginal-ring. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing